TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Emergency Response Africa (ERA), a leading healthcare technology company in partnership with the Ogun State government, has ...

Amy C. Edmondson is the Novartis Professor of Leadership and Management at Harvard Business School. Her latest book is Right ...

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate. The STIMULUS-MDS2 trial was ...

It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...

The crowd gathers for opening ceremonies at the “More Than Pink” walk in 2022 / photo by Chris Trela Bank of America is the ...

Behring, acquired in 2004, manufactures and distributes blood plasma products. Seqirus was formed by a rebranding of BioCSL ...

Credit card issuers, on average, reported solid metrics in August as net charge-offs declined and delinquencies moved up by ...

About 483,464 Nigerians have said that job losses and unemployment have led to them withdrawing over N200 billion from ...

Most medicines used worldwide are off-patent products – generic or biosimilar versions of branded medicines offering the same quality, safety, and efficacy at a lower price. They are the ‘silent ...